Lidocaine-d 6

Overview

Lidocaine-d 6 (Lignocaine-d 6 ) is deuterium labeled Lidocaine. Lidocaine (Lignocaine) inhibits sodium channels involving complex voltage and using dependence. Lidocaine decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine is an amide derivative and has potential for the research of ventricular arrhythmia.

Application

Products | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Signaling Pathways > Others | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Research Areas > Cardiovascular Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Sodium Channel | Products > Signaling Pathways > ERK | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > MEK | Products > Signaling Pathways > Isotope-Labeled Compounds | Products > Signaling Pathways > NF-κB

Product Information

• Catalog No.: HY-B0185S2
• CAS No.: 1215823-29-2
• Molecular Formula: C14H16D6N2O
• Molecular Weight: 240.37
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source